Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402

Gregory Cairncross, Meihua Wang, Edward Shaw, Robert Jenkins, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperriere, Walter Curran, Minesh Mehta

Research output: Contribution to journalArticlepeer-review

625 Scopus citations

Abstract

Purpose: Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown Patients and Methods: Eligible patients with AO/AOA were randomly assigned to procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) versus RT alone. The primary end point was overall survival (OS) Results: Two hundred ninety-one eligible patients were randomly assigned: 148 to PCV plus RT and 143 to RT. For the entire cohort, there was no difference in median survival by treatment (4.6 years for PCV plus RT v 4.7 years for RT; hazard ratio [HR] = 0.79; 95% CI, 0.60 to 1.04; P =.1). Patients with codeleted tumors lived longer than those with noncodeleted tumors (PCV plus RT: 14.7 v2.6 years, HR = 0.36, 95% CI, 0.23 to 0.57, P <.001; RT: 7.3 v 2.7 years, HR = 0.40, 95% CI, 0.27 to 0.60, P <.001), and the median survival of those with codeleted tumors treated with PCV plus RT was twice that of patients receiving RT (14.7 v7.3 years; HR = 0.59; 95% CI, 0.37 to 0.95; P =.03). For those with noncodeleted tumors, there was no difference in median survival by treatment arm (2.6 v 2.7 years; HR = 0.85; 95% CI, 0.58 to 1.23; P =.39). In Cox models that ncluded codeletion status, the adjusted OS for all patients was prolonged by PCV plus RT (HR = 0.67; 95% CI, 0.50 to 0.91; P =.01) Conclusion: For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.

Original languageEnglish (US)
Pages (from-to)337-343
Number of pages7
JournalJournal of Clinical Oncology
Volume31
Issue number3
DOIs
StatePublished - Jan 20 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402'. Together they form a unique fingerprint.

Cite this